Strain AI vs VX1+
AI Verdict
Choose Strain AI if…
Choose Strain AI if you require an FDA-cleared, AI-powered solution for the diagnostic assessment of adult cardiac function, particularly for conditions like heart failure or cardiotoxicity. This tool excels at analyzing cardiac ultrasound images to provide quantitative Global Longitudinal Strain (GLS) measurements, offering real-time, on-device insights to aid in early detection and management. Its offline capability makes it suitable for environments where internet connectivity may be a concern.
View Strain AI →Choose VX1+ if…
Choose VX1+ if you are an electrophysiologist performing cardiac ablation procedures for atrial fibrillation or atrial tachycardia and need real-time, AI-driven guidance. This software assists in the immediate identification of abnormal electrograms and spatio-temporal dispersed electrograms (DEs) directly within your existing EP recording and 3D mapping systems. It is designed to enhance procedural efficiency and precision during these complex interventions.
View VX1+ →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Strain AI | VX1+ |
|---|---|---|
| Deployment | API, Integrations with POS and menu sync platforms (Dutchie, Leafly, Weedmaps, Jane POS, Treez) | Software, compatible with most multipolar catheters and mapping technologies used in operating rooms or electrophysiology labs. |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Strain AITool A (Strain AI) emphasizes 'without manual image interpretation' and 'on-device AI, operates without internet connection', suggesting a highly automated and self-contained workflow that could be simpler to integrate and use. While Tool B (VX1+) offers a 'simple user interface with color coding' and 'manual or automatic annotation', Tool A's approach appears to minimize user intervention for diagnostic tasks.
Clinical Value
VX1+Tool B (VX1+) demonstrates stronger clinical value through multiple published studies, including the Ev-AIFib-Proof-of-Concept-Study and the RESTART trial, which showed significant improvements in freedom from atrial fibrillation and quality of life post-ablation. Its TAILORED-AF randomized controlled trial results were also published in Nature Medicine. While Tool A (Strain AI) is FDA-cleared and aids in heart function assessment, the extensive and impactful clinical evidence for Tool B in interventional cardiology is more compelling.
Pricing & Value
TieBoth Tool A and Tool B lack publicly available pricing information, making a direct comparison of their cost-effectiveness impossible. Without transparent pricing models or specific economic evaluation studies for either product, it is not feasible to determine which offers better value.
Enterprise Readiness
Strain AITool A explicitly states it is HIPAA compliant and offers a Business Associate Agreement (BAA), which are crucial for healthcare organizations handling protected health information. While Tool B indicates an expectation of compliance and has a general compliance statement, Tool A's explicit confirmation provides greater assurance for enterprise-level adoption and data security protocols.
Innovation
VX1+Tool B (VX1+) stands out as the 'first FDA clearance for an AI based tool in interventional cardiac electrophysiology' and has received prestigious recognition, including the Prix Galien Award for Best Startup. Its real-time AI guidance during complex cardiac ablation procedures represents a significant and awarded innovation in a challenging clinical domain.
Support & Docs
TieNeither Tool A nor Tool B provides comprehensive information regarding dedicated support channels, detailed documentation, or training programs in the provided facts or web search results. While Tool B mentions a user manual and brochure, this limited information is insufficient to declare a clear winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Strain AI | VX1+ |
|---|---|---|
| Name | Strain AI | VX1+ |
| Company | Exo | Volta Medical |
| Primary Function | AI-powered medical software that analyzes cardiac ultrasound images to measure Global Longitudinal Strain (GLS), aiding physicians in assessing heart function and detecting conditions like heart failure and cardiotoxicity in adult patients. | AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia. |
| Key Measurement/Assistance | Measures Global Longitudinal Strain (GLS); aids in assessing heart function and detecting heart failure (CHF, HFpEF, HFrEF) and hypertrophy. | Real-time identification of spatio-temporal dispersed electrograms (DEs) during AF and AT procedures; provides AI-driven insights to assist electrophysiologists during ablation procedures. |
| Target Medical Specialties | Cardiology, Oncology, Radiology | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring Strain AI and VX1+.